Aff - Biotech Updates - Michigan 7 2022 FMPS
Aff - Biotech Updates - Michigan 7 2022 FMPS.docx
Indexed text preview
AFF—Biotech—Updates 1AC – Innovation that Excites Current uncertainty in US-NATO biotech industry has the potential to collapse the industry and deck innovation Jonathan Smith 22, 1-3-2022, "European Biotech Industry Braces as War Erupts in Ukraine," Jonathan Smith studied Neuroscience in the University of Bristol, trained mice in Eisai, Hertfordshire, for one year, received his Ph.D. at the University of Leicester,Labiotech.eu, https://www.labiotech.eu/trends-news/ukraine-war-europe-biotech// AL Europe has been blindsided by its biggest war in decades with Russia’s invasion of Ukraine. Amid a raging humanitarian crisis, the biotech industry is preparing for increasing economic uncertainty, cyber threats, and clinical trial disruptions. The invasion of Ukraine by Russian forces last week caused a widespread outcry from the European community. The geopolitical landscape has undergone a historic shift and the tragic consequences of the event are rippling out to the European biotech industry. “The conflict in Ukraine is above all an enormous and deplorable shock to all of us,” said Miguel Forte, CEO of the Belgian regenerative medicine specialist Bone Therapeutics. “Our thoughts should go for those people, both in Ukraine and Russia, directly affected by reckless and irresponsible leadership.” The crisis has many facets and the biotech industry in Europe is preparing itself for challenges on a number of fronts. The human crisis The human cost of the invasion is expected to be heavy, with deaths and injuries from the conflict currently numbering in the hundreds, and a growing number of refugees moving west. The supply of lifesaving medications to and from the region are already being disrupted; the World Health Organization recently reported an urgent shortage of oxygen for use in healthcare in Ukraine. Another factor at play is the clamping down on air travel and shipments to and from Russian companies. “The primary and immediate consequences will be affecting Ukraine, but the impact could also likely be felt in Russia and for the Russian population,” said Forte. He added that other countries could be hit indirectly by the chaos. For life science companies, the impact will be strong in countries close to the epicenter of the conflict, including the Baltic states and Eastern European nations. These countries are facing uncertainty from the neighboring crisis, and many resident companies have employees and close contacts in Ukraine. In the Lithuanian life sciences industry, there are “companies that have business units, collaborations, and clients in Ukraine, which now has stopped,” said Monika Paule, CEO of the Lithuanian gene editing specialist CasZyme. “Companies are willing to relocate their employees, move collaborations to other countries, but all hope to get back to operations in Ukraine when the conflict is over.” While countries close to the conflict face large challenges, Paule sees life science companies in these regions also playing a strong role in alleviating the situation. “The sector is ready to help Ukraine by all means during and after the conflict either with medical supplies or bringing business activities back to the country,” she said. Clinical trials caught in the middle European biotech companies now face delays to clinical trials that are being run in Ukraine and Russia. The two countries have increasingly contributed to international studies over the last 10 years thanks to easy access to patient populations; Forte told me there are currently about 500 ongoing studies in Ukraine and over three times more in Russia. The ability of the sponsors, contract research organizations, and suppliers to keep going during the invasion is limited. “We can expect centers in Ukraine to shut down immediately to protect its staff and patients,” said Antoine Papiernik, Managing Partner of the investment firm Sofinnova Partners. “For Russian centers, the integrity of data from those sites might be at stake, and trials that are reliant on those sites will likely be affected.” Overall, Forte advises that big pharma and biotech companies focus on maximizing the safety of clinical trial staff and participants in affected regions. To compensate for the trial shortfall, companies may ramp up recruitment efforts in countries away from the war zone. However, the shifts will likely mean that Ukrainian and Russian patients lose access to many experimental treatments. Even patients that are included in clinical trials in affected regions could have poorer monitoring from clinicians due to the challenging conditions. Financial consequences threaten biotech stocks In addition to the human tragedy caused by the events in Ukraine, financial aftershocks are expected. Many European nations have launched a volley of sanctions against Russia and its ally Belarus. These include bans on investments flowing to Russia-based banking and oil industries in addition to the removal of some Russian banks from SWIFT, the international financial transactions system. The current conflict and resulting sanctions on Russia could have direct and psychological repercussions on the overall business environment in Europe and scare off already risk-averse investors from the biotech scene. Forte sees less impact on early-stage private investment, but bad news for public biotech firms and life sciences companies at later stages of drug development. This blow comes as biotech stocks are already in an anemic situation due in part to inflation fears. “It was already tough in Europe since the beginning of the year, and it might worsen even more,” said Bertrand Delsuc, founder of the business intelligence firm Biotech Radar. “Cash is king, more than ever.” Nonetheless, Papiernik is confident that the biotech industry can pull through. “Biotech has, in the past, demonstrated resilience compared to many other industries,” said Papiernik. “Protecting human lives in the immediate term remains the priority, but I hope we can also preserve the infrastructure enabling us to develop drugs that will help patients in need over the long term.” Cyberthreats to life sciences grow Part of the modern military arsenal is cyberattacks, and cyber threats are growing as Europe and the US slap economic sanctions on Russia. “Several cybersecurity agencies and government bodies have warned about Russia’s ability to retaliate asymmetrically through cyber means,” said Charles Fracchia, CEO of the US firm BioBright. “This means that any sectors of the EU, NATO, and the US economy are likely to be targets, including critical sectors such as banking, healthcare, and life sciences. In life sciences, the threat is probably highest for critical operations such as vaccine manufacturing, biomanufacturing more broadly, and large clinical centers.” Life sciences companies have been caught in the crossfire in the past; the US big pharma MSD lost over €1B in 2017 when it was hit by malware known as ‘notPetya,’ designed by Russia to target Ukraine. It took until January 2022 for MSD to claw back damage payments from insurers. “The notPetya attack was ostensibly not targeted at [MSD], and yet, it had this enormous effect, thousands of miles away,” said Fracchia. “[MSD] was big enough to withstand this, but it is clear that our industry could not withstand a targeted attack, to say nothing of the smaller biotech’s ability to survive altogether.” To endure pressing threats from cyberattacks, biotech companies are advised to assess their security measures and keep them up to date. Europe’s biotech industry braces itself Despite the bleak conditions in Ukraine, there might be a silver lining in the long term. European countries are presenting an increasingly united front against Russia’s actions in Ukraine, which could strengthen links between Europe’s various life sciences hubs, and improve the supply chains of medicines to Ukraine. In addition, the EU is considering lowering its dependence on Russian fossil fuels by increasing investments in renewable energy. This move could benefit biotech companies that aim to usher in a circular bioeconomy. For now, there are numerous ways that biotech companies can weather the current geopolitical storm. Many biotech players have signed a pledge to halt business activities with Russian companies and investors. According to Paule, biotech companies can help the situation in Ukraine by focusing on how to use their contacts and resources to bring medical supplies to those in need, in addition to providing work to Ukrainians coming to the rest of Europe. And, as Forte added, biotech startups should be confident that their efforts will bear fruit in the difficult situation, “even if at this stage there seems to be little space for optimism.” Biotech revolution has the potential to create a new wave of innovation to solve for a litany of existential threats BUT effective regulation is key Michael Chui 20, 5-13-2020, "The Bio Revolution: Innovations transforming economies, societies, and our lives," McKinsey & Company, https://www.mckinsey.com/industries/life-sciences/our-insights/the-bio-revolution-innovations-transforming-economies-societies-and-our-lives//AL A confluence of advances in biological science and accelerating development of computing, automation, and artificial intelligence is fueling a new wave of innovation. This Bio Revolution could have significant impact on economies and our lives, from health and agriculture to consumer goods, and energy and materials. Some innovations come with profound risks rooted in the self-sustaining, self-replicating, and interconnected nature of biology that argue for a serious and sustained debate about how this revolution should proceed. Accidents can have major consequences—and, especially if used unethically or maliciously, manipulating biology could become a Pandora’s box that, once opened, unleashes lasting damage to the health of humans, ecosystems, or both. The risks are particularly acute because many of the materials and tools are relatively cheap and accessible. Moreover, tackling these risks is complicated by a multiplicity of jurisdictional and cultural value systems, which makes collaboration and coordination across countries difficult. Sidebar COVID-19 and bio innovations However, new biological applications are already improving our response to global challenges including climate change and pandemics. Global responses to the novel coronavirus—SARS-CoV-2—illustrated substantial advances in biological science in just the past few years. The speed with which scientists sequenced the virus’s genome—weeks rather than months—bore witness to the new world of biology described in this research. However, sequencing is just the start: biological innovations are enabling the rapid introduction of clinical trials of vaccines, the search for effective therapies, and a deep investigation of both the origins and the transmission patterns of the virus. As much as 60 percent of the physical inputs to the global economy could, in principle, be produced biologically—about one-third of these inputs are biological materials (wood or animals bred for food) and the remaining two-thirds are nonbiological (plastics or fuels) but could potentially be produced or substituted using biology. Therefore, it is possible that bio innovations could impact up to 60 percent of physical inputs, although attaining that full potential is a long way off. Even modest progress toward it could transform economies, societies, and our lives, including what we eat and wear, the medicines we take, the fuels we use, and how we construct our physical world. In human health, at least 45 percent of the current global disease burden could be addressed using science that is conceivable today. A pipeline of about 400 use cases, almost all scientifically feasible today, is already visible. These applications alone could have direct economic impact of up to $4 trillion a year over the next ten to 20 years. More than half of this direct impact could be outside human health in domains such as agriculture and food, consumer products and services, and materials and energy production. Taking into account potential knock-on effects, new applications yet to emerge, and additional scientific breakthroughs, the full potential could be far larger. We isolate 2 internal link’s to disease spread 1-- Innovation can push back against the threat of mass disease spread through vaccine creation, disease detection systems, and biosecurity preparedness Hamish De Bretton-Gordon 20, Hamish de Bretton-Gordon is a highly operationally experienced CBRN practitioner and a leading expert in chemical and biological counterterrorism and warfare. He was the commanding officer of the U.K. Chemical, Biological, Radiological and Nuclear (CBRN) Regiment and NATO’s Rapid Reaction CBRN Battalion He advises the British Ministry of Defence and the Foreign Office on CBRN and is the Distinguished Visiting Fellow at Magdalene College Cambridge 2020-21. "Biosecurity in the Wake of COVID-19: The Urgent Action Needed – Combating Terrorism Center at West Point," Combating Terrorism Center at West Point, https://ctc.usma.edu/biosecurity-in-the-wake-of-covid-19-the-urgent-action-needed// AL With a quarter of a million dead in the United States and more than a million globally, a massive economic toll,a and a second wave in full swing in the northern hemisphere, the United States and other countries are paying a price for years of neglecting biosecurity as a top-tier national security priority. For years, biosecurity has been the poor relation of the ‘other’ securities for one simple reason: policymakers and analysts failed to grasp just how devastating a highly transmissible new virus in a highly interconnected world could be, and viewed a devastating global pandemic or catastrophic bioterror attack as very unlikely. This article first describes how the COVID-19 pandemic has upended such assumptions, requiring policymakers to rethink both the potential impact and likelihood of the most concerning biological threats (bio threats). Based on this author’s decades of experience confronting CBRN threats,c it then makes a series of observations on the approach now needed to counter biological threats. Some have seen this crisis as a one-in-a-100-year event. But, as this article will outline, this is both naïve and risks creating complacency. Unless countries around the world develop a comprehensive biosecurity strategy and coordinate their efforts, pandemics (either natural or engineered) could devastate the planet every decade. The New Bio Threat Horizon The Need to Rethink Potential Impact Policymakers around the world did not grasp just how large the impact of a bio threat could be. Beyond the enormous human and economic impact, the current pandemic has exposed the weakness, lack of preparedness, and poor responsiveness of healthcare systems of even highly developed countries like the United States and the United Kingdom. And the virus has inflicted carnage, even though SARS-CoV-2 (the virus that causes COVID-19) is not especially virulent. The world may be confronted with other viruses in the future whose combination of virulence (the harm a pathogen does to its host), transmissibility, and other characteristics pose much greater danger. While overwhelming evidence points to SARS-CoV-2 spontaneously spreading to humans, the advances in synthetic biology and the growth in the number of Level 3 and 4 biocontainment facilities around the world storing deadly viruses1 mean there is also the very real possibility that in the future, bad actors will try to engineer or steal/obtain a highly transmissible and highly virulent virus and unleash it onto the world. Another risk is accidental releases from such biocontainment facilities. COVID-19, a highly transmissible but not very virulent pathogen, has had a devastating global impact, a fact that will not have gone unnoticed by rogue states and terror organizations. Advances in synthetic biology have created tools that could be put to malevolent use. In the last two decades, scientists synthesized the poliovirus from its genetic sequence,2 recreated the 1918 Spanish flu virus,3 and succeeded in modifying the H5N1 avian flu virus so that it resulted (in a research laboratory) in airborne transmission among mammals.4 In the future, we should think of weaponized biology as no less of an existential threat to the planet than weaponized atomic science. It should also be noted that the fear and panic that even a medium-scale bioterror attack could create could have dangerous implications that may rival or even surpass the immediate loss of life. The Need to Rethink Likelihood Given the fact that in late 2019 when, as far as is known, COVID-19 cases first started emerging in China, it had been more than a century since the previous catastrophic outbreak (the 1918-1919 “Spanish flu” pandemic),d it was unsurprising that many thought of such pandemics as a one-in-a-100-year event. Such assumptions should no longer hold. The encroachment of human settlements into areas that had previously been sanctuaries for wildlife5 and the popularity in some parts of the world of markets where people and wild animals are brought into proximity have made it more likely viruses will make the species leap to human beings.e And when they do, as the COVID-19 pandemic illustrated, the interconnectedness of a world in which millions of people fly each day6 means they can spread very rapidly. There is also growing concern about engineered viruses. Not only have advances in synthetic biology (SynBio) created growing capacity for extremely dangerous viruses to be engineered in a laboratory, but the number of people with access to potentially dangerous ‘dual use’ technology has greatly expanded and continues to expand, making malevolent use of such technology ever more likely. In the August 2020 issue of this publication, scientists at the U.S. Military Academy at West Point warned that: The wide availability of the protocols, procedures, and techniques necessary to produce and modify living organisms combined with an exponential increase in the availability of genetic data is leading to a revolution in science affecting the threat landscape that can be rivaled only by the development of the atomic bomb. As the technology improves, the level of education and skills necessary to engineer biological agents decreases. Whereas only state actors historically had the resources to develop and employ biological weapons, SynBio is changing the threat paradigm. The cost threshold of engineering viruses is also lowering, with the West Point scientists warning that synthetic biology has “placed the ability to recreate some of the deadliest infectious diseases known well within the grasp of the state-sponsored terrorist and the talented non-state actor.”7 As already noted, another source of vulnerability is that deadly viruses could be stolen from or escape from a research laboratory. There are now around 50 Biosafety Level 4f facilities around the world, where the deadliest pathogens are stored and worked on, and this figure is set to increase in the next few years.g This is a large increase over the last 30 years, creating bigger risk of a breach. Of equal, if not greater concern are the thousands of Biosafety Level 3 labs globally,8 which handle deadly pathogens like COVID-19.9 Given what has been outlined above, the risk of a future destructive biological attack or another devastating global pandemic should no longer be seen as low. From this point forward, there should no higher priority for the international community than biosecurity. Hamish de Bretton-Gordon Improving Biosecurity 2-- Only cooperating internationally with NATO prevents a biological arm’s race that increases the risk of disease outbreak Steve Fyffe 15, 12-17-2015, Steve earned his Master of Journalism degree from UC Berkeley, and served in
Preview shortened. Download the file for the full document.